BLASINGLE-USEVIALPriority Review
Approved
Feb 2008
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
12
Data completeness
5/8 — Partial
Priority Review
ARCALYST (rilonacept) by Kiniksa Pharmaceuticals is interleukin-1 alpha (il-1α) and interleukin-1 beta (il-1β) cytokine trap. First approved in 2008.
Drug data last refreshed 7h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ARCALYST (rilonacept) is a fusion protein cytokine trap that blocks interleukin-1 alpha and beta signaling by acting as a soluble decoy receptor. It is indicated for rare autoinflammatory syndromes including CAPS (Cryopyrin-Associated Periodic Syndromes) and DIRA (Deficiency of Interleukin-1 Receptor Antagonist), as well as recurrent pericarditis. Rilonacept prevents IL-1 mediated inflammation by binding both IL-1α and IL-1β with extremely high affinity (Kd 0.5-1.4 pM), blocking their interaction with cell surface IL-1 receptors.
$0.025BPart D
LOE ApproachingProduct is in LOE-approaching stage with modest Part D spending of $25M and only 1,082 claims in 2023, suggesting a small but stable patient base in orphan/rare disease with limited commercial expansion opportunities.
Mechanism of Action
interleukin-1 alpha (IL-1α) and interleukin-1 beta (IL-1β) cytokine trap. Rilonacept blocks IL-1 signaling by acting as a soluble decoy receptor that binds both IL-1α and IL-1β and prevents its interaction with cell surface receptors. Rilonacept also binds interleukin-1 receptor antagonist…
Indications
Worked on ARCALYST at Kiniksa Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.